Kyverna Therapeutics, Inc.(KYTX)

$8.37—

Chart

Kyverna Therapeutics, Inc.(KYTX)

NASDAQ

$8.37—

Chart Studio

KYTX(KYTX)

KYTX

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.68

Nov 11, 2026

Analyst Sentiment

Wall St. Consensus

Buy

4 analysts·Low coverage

Score

4 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

4100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$25.00

+198.7%

Consensus

$25.00

+198.7%

Bull

$25.00

+198.7%

12-Month Target Range4 analysts

$25.00$25.00$25.00

Current $8.37Consensus

Current Price

$8.37

Upside to Consensus

$16.63

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+21.30%

EPS—

FY2028

Rev+251.50%

EPS—

FY2029

Rev+227.52%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$13M	$15M	$53M	$175M	$524M
Low	$7M	$6M	$40M	$95M	$284M
High	$23M	$31M	$64M	$315M	$945M
EBITDA Avg	$-120M	$-133M	$-100M	$-156M	$-36M
Low	$-123M	$-162M	$-131M	$-323M	$-85M
High	$-117M	$-104M	$-69M	$-61M	$-8M
EBIT Avg	$-121M	$-134M	$-102M	$-160M	$-46M
Low	$-125M	$-163M	$-133M	$-327M	$-95M
High	$-118M	$-105M	$-71M	$-64M	$-19M
Net Income Avg	$-122M	$-135M	$-102M	$-160M	$-46M
Low	$-125M	$-163M	$-134M	$-327M	$-95M
High	$-119M	$-106M	$-71M	$-65M	$-19M
EPS Avg	$-2.76	$-3.03	$-2.31	$-3.61	$-1.05
Low	$-2.82	$-3.69	$-3.02	$-7.38	$-2.15
High	$-2.68	$-2.39	$-1.61	$-1.46	$-0.43
Analysts (Rev / EPS)	4 / 5	4 / 5	4 / 4	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	—	—	$1M	$2M	$5M	$19M	—	—
Low	—	—	$1M	$2M	$5M	$19M	—	—
High	—	—	$1M	$2M	$5M	$19M	—	—
EBITDA Avg	—	—	$-47M	$-41M	$-39M	$-32M	—	—
Low	—	—	$-47M	$-41M	$-39M	$-32M	—	—
High	—	—	$-47M	$-41M	$-39M	$-32M	—	—
EBIT Avg	—	—	$-48M	$-42M	$-40M	$-32M	—	—
Low	—	—	$-48M	$-42M	$-40M	$-32M	—	—
High	—	—	$-48M	$-42M	$-40M	$-32M	—	—
Net Income Avg	$-42M	$-48M	$-49M	$-42M	$-40M	$-33M	$-16M	$-6M
Low	$-43M	$-50M	$-49M	$-42M	$-40M	$-33M	$-16M	$-6M
High	$-40M	$-44M	$-49M	$-42M	$-40M	$-33M	$-16M	$-6M
EPS Avg	$-0.69	$-0.78	$-0.80	$-0.70	$-0.66	$-0.54	$-0.27	$-0.10
Low	$-0.71	$-0.83	$-0.80	$-0.70	$-0.66	$-0.54	$-0.27	$-0.10
High	$-0.66	$-0.73	$-0.80	$-0.70	$-0.66	$-0.54	$-0.27	$-0.10
Analysts (Rev / EPS)	— / 4	— / 4	1 / 1	1 / 1	1 / 1	1 / 1	— / 2	— / 2

Earnings Surprises

Recent Analyst Actions

May 15, 2026H.C. Wainwright

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

Target:$25.00

+132.8%from $10.74

Dec 16, 2025Wells Fargo

Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo

Target:$33.00

+205.3%from $10.81

Dec 15, 2025UBS

Leerink raises Kyverna price target, says KYSA-8 study results transformative

Target:$32.00

+196.0%from $10.81

Dec 15, 2025Morgan Stanley

Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley

Target:$33.00

+205.3%from $10.81

Dec 4, 2025Morgan Stanley

Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley

Target:$25.00

+220.9%from $7.79

Oct 27, 2025H.C. Wainwright

Kyverna Therapeutics price target raised to $20 from $10 at H.C. Wainwright

Target:$20.00

+168.8%from $7.44

Aug 29, 2025H.C. Wainwright

Kyverna Therapeutics price target raised to $10 from $5 at H.C. Wainwright

Target:$10.00

+169.5%from $3.71

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance